{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:53:47Z","timestamp":1788274427769,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"DOI":"10.1007\/s00066-026-02570-9","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:53:35Z","timestamp":1783666415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations"],"prefix":"10.1007","author":[{"given":"Carlo Guglielmo","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0436","authenticated-orcid":false,"given":"Giulia","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Galetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Nardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Placidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"1","key":"2570_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","volume":"25","author":"EB Golden","year":"2015","unstructured":"Golden\u00a0EB, Apetoh\u00a0L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25(1):11\u201317","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"2570_CR2","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.3390\/curroncol29070366","volume":"29","author":"F Iori","year":"2022","unstructured":"Iori\u00a0F, Bruni\u00a0A, Cozzi\u00a0S, Ciammella\u00a0P, Di Pressa\u00a0F, Boldrini\u00a0L, Greco\u00a0C, Nardone\u00a0V, Salvestrini\u00a0V, Desideri\u00a0I, De Felice\u00a0F, Iotti\u00a0C (2022) Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation. Curr Oncol 29(7):4612\u20134624","journal-title":"Curr Oncol"},{"issue":"11","key":"2570_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova\u00a0J, Kepp\u00a0O, Kasikova\u00a0L et\u00a0al (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 11(11):1013","journal-title":"Cell Death Dis"},{"issue":"5","key":"2570_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng\u00a0L, Liang\u00a0H, Xu\u00a0M et\u00a0al (2014) STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type\u00a0I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 41(5):843\u2013852","journal-title":"Immunity"},{"issue":"24","key":"2570_CR5","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-6049","volume":"10","author":"NH Wang","year":"2022","unstructured":"Wang\u00a0NH, Lei\u00a0Z, Yang\u00a0HN et\u00a0al (2022) Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann Transl Med 10(24):1406","journal-title":"Ann Transl Med"},{"issue":"6","key":"2570_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","volume":"121","author":"K Yoneda","year":"2019","unstructured":"Yoneda\u00a0K, Kuwata\u00a0T, Kanayama\u00a0M et\u00a0al (2019) Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer 121(6):490\u2013496","journal-title":"Br J Cancer"},{"issue":"18","key":"2570_CR7","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2217\/imt-2020-0289","volume":"13","author":"M Massaccesi","year":"2021","unstructured":"Massaccesi\u00a0M, Boldrini\u00a0L, Romano\u00a0A, Rossi\u00a0E, Schinzari\u00a0G, Lepre\u00a0E, Gambacorta\u00a0MA, Valentini\u00a0V (2021) Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a\u00a0case report. Immunotherapy 13(18):1457\u20131463","journal-title":"Immunotherapy"},{"key":"2570_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tipsro.2020.02.003","volume":"14","author":"M Massaccesi","year":"2020","unstructured":"Massaccesi\u00a0M, Boldrini\u00a0L, Piras\u00a0A, Stimato\u00a0G, Quaranta\u00a0F, Azario\u00a0L, Mattiucci\u00a0GC, Valentini\u00a0V (2020) Spatially fractionated radiotherapy (SFRT) targeting the hypoxic tumor segment for the intentional induction of non-targeted effects: An in silico study to exploit a new treatment paradigm. Tech Innov Patient Support Radiat Oncol 14:11\u201314","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"17","key":"2570_CR9","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan\u00a0MZ, Galloway\u00a0AE, Kawashima\u00a0N et\u00a0al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA\u20114 antibody. Clin Cancer Res 15(17):5379\u20135388","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2570_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157164","volume":"11","author":"KH Young","year":"2016","unstructured":"Young\u00a0KH, Baird\u00a0JR, Savage\u00a0T et\u00a0al (2016) Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS One 11(6):e0157164","journal-title":"PLoS One"},{"issue":"58","key":"2570_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg0117","volume":"6","author":"J Wei","year":"2021","unstructured":"Wei\u00a0J, Montalvo-Ortiz\u00a0W, Yu\u00a0L et\u00a0al (2021) Sequence of \u03b1PD\u20111 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol 6(58):eabg0117","journal-title":"Sci Immunol"},{"issue":"9","key":"2570_CR12","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen\u00a0WSME, Peulen\u00a0HMU, Lalezari\u00a0F et\u00a0al (2019) Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol 5(9):1276\u20131282","journal-title":"JAMA Oncol"},{"key":"2570_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box\u00a0C, Alard\u00a0A, Aryankalayil\u00a0MJ et\u00a0al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618","journal-title":"Nat Commun"},{"issue":"1","key":"2570_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-025-02366-y","volume":"24","author":"Q Zeng","year":"2025","unstructured":"Zeng\u00a0Q, Liu\u00a0M, Wang\u00a0Z et\u00a0al (2025) Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy. Mol Cancer 24(1):176\u2013176","journal-title":"Mol Cancer"},{"issue":"1","key":"2570_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12951-025-03229-w","volume":"23","author":"X Hu","year":"2025","unstructured":"Hu\u00a0X, Zhu\u00a0H, Shen\u00a0Y et\u00a0al (2025) Metal-organic framework nanoparticles activate cGAS-STING pathway to improve radiotherapy sensitivity. J\u00a0Nanobiotechnology 23(1):131\u2013131","journal-title":"J Nanobiotechnology"},{"key":"2570_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251387534","volume":"17","author":"X Chen","year":"2025","unstructured":"Chen\u00a0X, Yang\u00a0M, Huang\u00a0Y et\u00a0al (2025) Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy. Ther Adv Med Oncol 17:17588359251387534","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"2570_CR17","first-page":"773","volume":"24","author":"B Fionda","year":"2020","unstructured":"Fionda\u00a0B, Massaccesi\u00a0M, Tagliaferri\u00a0L, Dinapoli\u00a0N, Iezzi\u00a0R, Boldrini\u00a0L (2020) Abscopal effect and interventional oncology: state of art and future perspectives. Eur Rev Med Pharmacol Sci 24(2):773\u2013776","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2570_CR18","doi-asserted-by":"crossref","unstructured":"Gupta G, Goddard A, McDonald S, et\u00a0al. PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity. Research Square. 2025 [PREPRINT]","DOI":"10.21203\/rs.3.rs-7881707\/v1"},{"issue":"3","key":"2570_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/cancers17030391","volume":"17","author":"SY Lee","year":"2025","unstructured":"Lee\u00a0SY, Jeong\u00a0EK, Ju\u00a0MK et\u00a0al (2025) Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation. Cancers 17(3):391\u2013391","journal-title":"Cancers"},{"issue":"7","key":"2570_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271205","volume":"17","author":"S Katsuki","year":"2022","unstructured":"Katsuki\u00a0S, Minami\u00a0K, Oniwa\u00a0K et\u00a0al (2022) Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma. PLoS ONE 17(7):e0271205","journal-title":"PLoS ONE"},{"issue":"1","key":"2570_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011487","volume":"13","author":"PA Laurent","year":"2025","unstructured":"Laurent\u00a0PA, Morel\u00a0D, Meziani\u00a0L et\u00a0al (2025) Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect. J\u00a0Immunother Cancer 13(1):e011487","journal-title":"J Immunother Cancer"},{"key":"2570_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2326-6066.CIR-24-0610","volume":"13","author":"SA Sakai","year":"2024","unstructured":"Sakai\u00a0SA, Saeki\u00a0K, Chi\u00a0SG et\u00a0al (2024) Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration. Cancer Immunol Res 13:353\u2013364","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2570_CR23","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","volume":"7","author":"JW Welsh","year":"2019","unstructured":"Welsh\u00a0JW, Tang\u00a0C, de Groot\u00a0P et\u00a0al (2019) Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903\u20131909","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2570_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1046028","volume":"4","author":"RA Chandra","year":"2015","unstructured":"Chandra\u00a0RA, Wilhite\u00a0TJ, Balboni\u00a0TA et\u00a0al (2015) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology 4(10):e1046028","journal-title":"OncoImmunology"},{"issue":"9","key":"2570_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091305","volume":"12","author":"N Kim","year":"2023","unstructured":"Kim\u00a0N, Jiang\u00a0W, Bhatt\u00a0DL et\u00a0al (2023) A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA\u20114 Immune Checkpoint Inhibitors. Cells 12(9):1305","journal-title":"Cells"},{"issue":"1","key":"2570_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01503-8","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai\u00a0L, Li\u00a0Y, Tan\u00a0J et\u00a0al (2023) Targeting LAG\u20113, TIM\u20113, and TIGIT for cancer immunotherapy. J\u00a0Hematol Oncol 16(1):105","journal-title":"J Hematol Oncol"},{"key":"2570_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231186027","volume":"15","author":"F Kreidieh","year":"2023","unstructured":"Kreidieh\u00a0F, Tawbi\u00a0H (2023) The introduction of LAG\u20113 checkpoint blockade in melanoma: immunotherapy landscape beyond PD\u20111 and CTLA\u20114 inhibition. Ther Adv Med Oncol 15:17588359231186027","journal-title":"Ther Adv Med Oncol"},{"key":"2570_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217935","volume":"631","author":"C Wang","year":"2025","unstructured":"Wang\u00a0C, Han\u00a0L, Zhang\u00a0J et\u00a0al (2025) Radiotherapy in combination with PD\u20111 and TIGIT blockade mediate antitumor abscopal effects and immune memory via CD8+ T cells. Cancer Lett 631:217935","journal-title":"Cancer Lett"},{"key":"2570_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1568664","volume":"16","author":"K Ghasemi","year":"2025","unstructured":"Ghasemi\u00a0K (2025) Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Front Pharmacol 16:1568664","journal-title":"Front Pharmacol"},{"key":"2570_CR30","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer\u00a0N, Janicka\u00a0N, Szlasa\u00a0W et\u00a0al (2023) TIM\u20113 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother 72:3405\u20133425","journal-title":"Cancer Immunol Immunother"},{"issue":"21","key":"2570_CR31","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","volume":"24","author":"AJ Oweida","year":"2018","unstructured":"Oweida\u00a0AJ, Hararah\u00a0MK, Phan\u00a0A et\u00a0al (2018) Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM\u20113 Upregulation and Regulatory T\u2011Cell Infiltration. Clin Cancer Res 24(21):5368\u20135380","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2570_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s12951-022-01621-4","volume":"20","author":"Y Hu","year":"2022","unstructured":"Hu\u00a0Y, Paris\u00a0S, Bertolet\u00a0G et\u00a0al (2022) Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J\u00a0Nanobiotechnology 20(1):417\u2013417","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"2570_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/curroncol32040230","volume":"32","author":"C Mire\u0219tean","year":"2025","unstructured":"Mire\u0219tean\u00a0C, Iancu\u00a0R, Iancu\u00a0D (2025) LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy. Curr Oncol 32(4):230\u2013230","journal-title":"Curr Oncol"},{"issue":"3","key":"2570_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cncr.35063","volume":"130","author":"A Knisely","year":"2024","unstructured":"Knisely\u00a0A, Ahmed\u00a0J, Torrado\u00a0C et\u00a0al (2024) Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400\u2013409","journal-title":"Cancer"},{"issue":"5","key":"2570_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-24-2770","volume":"31","author":"T Shree","year":"2025","unstructured":"Shree\u00a0T, Bhatt\u00a0S, Advani\u00a0RH et\u00a0al (2025) A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies. Clin Cancer Res 31(5):868\u2013880","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2570_CR36","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","volume":"8","author":"MJ Frank","year":"2018","unstructured":"Frank\u00a0MJ, Reagan\u00a0PM, Bartlett\u00a0NL et\u00a0al (2018) In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discov 8(10):1258\u20131269","journal-title":"Cancer Discov"},{"issue":"10","key":"2570_CR37","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas\u00a0A, Medina\u00a0T, Kummar\u00a0S et\u00a0al (2018) SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov 8(10):1250\u20131257","journal-title":"Cancer Discov"},{"issue":"1","key":"2570_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera\u00a0FG, Ronet\u00a0C, Ochoa de Olza\u00a0M et\u00a0al (2022) Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov 12(1):108\u2013133","journal-title":"Cancer Discov"},{"key":"2570_CR39","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/IJN.S515893","volume":"20","author":"Y Qiao","year":"2025","unstructured":"Qiao\u00a0Y, Wei\u00a0L, Su\u00a0Y et\u00a0al (2025) Nanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy. Int J Nanomedicine 20:5429\u20135456","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"2570_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60769-3","volume":"16","author":"X Yin","year":"2025","unstructured":"Yin\u00a0X, Ding\u00a0Z, Yu\u00a0L et\u00a0al (2025) Orchestrating intratumoral DC\u2011T cell immunity for enhanced tumor control via radiotherapy-activated TLR7\/8 prodrugs in mice. Nat Commun 16(1):6020","journal-title":"Nat Commun"},{"key":"2570_CR41","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.7150\/thno.54881","volume":"11","author":"J Jagodinsky","year":"2021","unstructured":"Jagodinsky\u00a0J, Jin\u00a0W, Bates\u00a0A et\u00a0al (2021) Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics 11:6120\u20136137","journal-title":"Theranostics"},{"issue":"3","key":"2570_CR42","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/mp.15184","volume":"49","author":"A Friedl","year":"2022","unstructured":"Friedl\u00a0A, Prise\u00a0K, Butterworth\u00a0K et\u00a0al (2022) Radiobiology of the flash effect. Med Phys 49(3):1993\u20132013","journal-title":"Med Phys"},{"key":"2570_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052546","volume":"25","author":"A Borghini","year":"2024","unstructured":"Borghini\u00a0A, Labate\u00a0L, Piccinini\u00a0S et\u00a0al (2024) FLASH Radiotherapy: Expectations, Challenges, and Current Knowledge. Int J Mol Sci 25:2546","journal-title":"Int J Mol Sci"},{"key":"2570_CR44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/09553002.2021.2004328","volume":"98","author":"H Kacem","year":"2021","unstructured":"Kacem\u00a0H, Almeida\u00a0A, Cherbuin\u00a0N et\u00a0al (2021) Understanding the FLASH effect to unravel the potential of ultra-high dose rate irradiation. Int J Radiat Biol 98:506\u2013516","journal-title":"Int J Radiat Biol"},{"issue":"11","key":"2570_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.clon.2021.09.003","volume":"33","author":"Y Zhang","year":"2021","unstructured":"Zhang\u00a0Y, Ding\u00a0Z, Perentesis\u00a0J et\u00a0al (2021) Can Rational Combination of Ultra-high Dose Rate FLASH Radiotherapy with Immunotherapy Provide a Novel Approach to Cancer Treatment? Clin Oncol 33(11):713\u2013722","journal-title":"Clin Oncol"},{"issue":"2","key":"2570_CR46","first-page":"164","volume":"205","author":"T Yu","year":"2026","unstructured":"Yu\u00a0T, Yoon\u00a0Y, Choi\u00a0CW et\u00a0al (2026) Effects of Ultra-High Dose-Rate Radiotherapy (FLASH-RT) on the Hematopoietic and Immune Systems: An Animal Study. Radiat Res 205(2):164\u2013174","journal-title":"Radiat Res"},{"key":"2570_CR47","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.ijrobp.2023.10.031","volume":"118","author":"A Almeida","year":"2023","unstructured":"Almeida\u00a0A, Godfroid\u00a0C, Leavitt\u00a0RJ et\u00a0al (2023) Antitumor Effect by Either FLASH or Conventional Dose Rate Irradiation Involves Equivalent Immune Responses. Int J Radiat Oncol Biol Phys 118:1110\u20131122","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2570_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jrr\/rrae091","volume":"66","author":"S Katsuki","year":"2024","unstructured":"Katsuki\u00a0S, Minami\u00a0K, Oniwa\u00a0K et\u00a0al (2024) Ultra-high dose rate (FLASH) carbon ion irradiation inhibited immune suppressive protein expression on Pan02 cell line. J\u00a0Radiat Res 66:97\u2013102","journal-title":"J Radiat Res"},{"key":"2570_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102183","volume":"51","author":"Y Wang","year":"2024","unstructured":"Wang\u00a0Y, Qi\u00a0S, Bi\u00a0N et\u00a0al (2024) FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics. Transl Oncol 51:102183","journal-title":"Transl Oncol"},{"key":"2570_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101273","volume":"17","author":"M Moreau","year":"2025","unstructured":"Moreau\u00a0M, Kelly\u00a0K, Mao\u00a0S et\u00a0al (2025) Leveraging the Immune Response from LIFE Biomaterial and Photon-Flash in Pre-Clinical Pancreatic Cancer Treatment. Pharmaceutics 17:1273","journal-title":"Pharmaceutics"},{"issue":"1","key":"2570_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41392-025-02184-0","volume":"10","author":"HS Li","year":"2025","unstructured":"Li\u00a0HS, Tang\u00a0R, Shi\u00a0H et\u00a0al (2025) Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma. Signal Transduct Target Ther 10(1):82","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2570_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/1535-7163.MCT-21-0358","volume":"21","author":"JT Eggold","year":"2022","unstructured":"Eggold\u00a0JT, Chow\u00a0S, Melemenidis\u00a0S et\u00a0al (2022) Abdominopelvic FLASH Irradiation Improves PD\u20111 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer. Mol Cancer Ther 21(3):371\u2013381","journal-title":"Mol Cancer Ther"},{"issue":"52","key":"2570_CR53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208506119","volume":"119","author":"X Shi","year":"2022","unstructured":"Shi\u00a0X, Lin\u00a0Y, Bergeron\u00a0E et\u00a0al (2022) FLASH X\u2011ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy. Proc Natl Acad Sci USA 119(52):e2208506119","journal-title":"Proc Natl Acad Sci USA"},{"key":"2570_CR54","first-page":"138","volume":"38","author":"H Zhu","year":"2023","unstructured":"Zhu\u00a0H, Xie\u00a0D, Yang\u00a0Y et\u00a0al (2023) Comparison of intratumor and local immune response between MV X\u2011ray FLASH and conventional radiotherapies. Clin Transl Radiat Oncol 38:138\u2013146","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2570_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16612-6","volume":"12","author":"E Liljedahl","year":"2022","unstructured":"Liljedahl\u00a0E, Ryd\u00e9n\u00a0L, Ceberg\u00a0C et\u00a0al (2022) Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma. Sci Rep 12(1):12285","journal-title":"Sci Rep"},{"issue":"22","key":"2570_CR56","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.1021\/acs.chemmater.3c01390","volume":"35","author":"X Dong","year":"2023","unstructured":"Dong\u00a0X, Liang\u00a0J, Yang\u00a0A et\u00a0al (2023) Novel Combination Treatment for Melanoma: FLASH Radiotherapy and Immunotherapy Delivered by a Radiopaque and Radiation Responsive Hydrogel. Chem Mater 35(22):9542\u20139551","journal-title":"Chem Mater"},{"key":"2570_CR57","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41416-024-02704-9","volume":"131","author":"A Karabou\u00e9","year":"2024","unstructured":"Karabou\u00e9\u00a0A, Innominato\u00a0PF, Wreglesworth\u00a0N et\u00a0al (2024) Why does circadian timing of administration matter for immune checkpoint inhibitors\u2019 efficacy? Br J Cancer 131:783\u2013796","journal-title":"Br J Cancer"},{"key":"2570_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41573-020-00109-w","volume":"20","author":"W Ruan","year":"2021","unstructured":"Ruan\u00a0W, Yuan\u00a0X, Eltzschig\u00a0H (2021) Circadian rhythm as a therapeutic target. Nat Rev Drug Discov 20:287\u2013307","journal-title":"Nat Rev Drug Discov"},{"key":"2570_CR59","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","volume":"187","author":"C Wang","year":"2024","unstructured":"Wang\u00a0C, Zeng\u00a0Q, G\u00fcl\u00a0ZM et\u00a0al (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. Cell 187:2690\u20132702.e17","journal-title":"Cell"},{"key":"2570_CR60","doi-asserted-by":"publisher","unstructured":"Lichterman JN, Srinivasan T, Wang R et\u00a0al (2025) Timing of immune checkpoint blockade shapes anti-tumor immunity via a\u00a0clock-dependent chemokine axis. https:\/\/doi.org\/10.1101\/2025.11.03.686293","DOI":"10.1101\/2025.11.03.686293"},{"key":"2570_CR61","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41590-024-01859-0","volume":"25","author":"B Fortin","year":"2024","unstructured":"Fortin\u00a0B, Pfeiffer\u00a0SM, Insua-Rodr\u00edguez\u00a0J et\u00a0al (2024) Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol 25:1257\u20131269","journal-title":"Nat Immunol"},{"key":"2570_CR62","doi-asserted-by":"crossref","unstructured":"Huang Z, Zeng L, Ruan Z, Zeng Q, et\u00a0al. Time-of-day immunochemotherapy in non-small cell lung cancer: a\u00a0randomized phase\u00a03\u00a0trial. Nat Med. 2026. Online ahead of print","DOI":"10.1038\/s41591-026-04508-1"},{"key":"2570_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102220","volume":"9","author":"T Landre","year":"2024","unstructured":"Landre\u00a0T, Karabou\u00e9\u00a0A, Buchwald\u00a0Z et\u00a0al (2024) Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open 9:102220","journal-title":"ESMO Open"},{"issue":"1","key":"2570_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae197","volume":"30","author":"K Fletcher","year":"2025","unstructured":"Fletcher\u00a0K, Rehman\u00a0S, Irlmeier\u00a0R et\u00a0al (2025) Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. Oncologist 30(1):oyae197","journal-title":"Oncologist"},{"key":"2570_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1512972","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng\u00a0Y, Shi\u00a0F, Sun\u00a0L et\u00a0al (2024) Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis. Front Immunol 15:1512972","journal-title":"Front Immunol"},{"key":"2570_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020408","volume":"15","author":"M Santoni","year":"2023","unstructured":"Santoni\u00a0M, Molina-Cerrillo\u00a0J, Santoni\u00a0G et\u00a0al (2023) Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15:408","journal-title":"Cancers"},{"key":"2570_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104269","volume":"84","author":"A Webb","year":"2022","unstructured":"Webb\u00a0A, Harper\u00a0E, Rattay\u00a0T et\u00a0al (2022) Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort. eBioMedicine 84:104269","journal-title":"eBioMedicine"},{"key":"2570_CR68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/clockssleep6010014","volume":"6","author":"N Nelson","year":"2024","unstructured":"Nelson\u00a0N, Burke\u00a0SE, Cappelli\u00a0L et\u00a0al (2024) Temporal Considerations in Brain Metastases Radiation Therapy: The Intersection of Chronobiology and Patient Profiles. Clocks Sleep 6:200\u2013210","journal-title":"Clocks Sleep"},{"key":"2570_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100608","volume":"20","author":"G Lohith","year":"2023","unstructured":"Lohith\u00a0G, Sekar\u00a0K, Kallur\u00a0K et\u00a0al (2023) 136P Circadian rhythm positioned chronomodulated-SBRT with cancer associated fibroblast elimination theranostic treatment. Immuno-Oncol Technol 20:100608","journal-title":"Immuno-Oncol Technol"},{"key":"2570_CR70","doi-asserted-by":"publisher","DOI":"10.1200\/CCI-24-00160","volume":"9","author":"A Li","year":"2025","unstructured":"Li\u00a0A, Lou\u00a0E, Leder\u00a0K et\u00a0al (2025) Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response. JCO Clin Cancer Inform 9:e2400160","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"2570_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02462-y","volume":"23","author":"Y Fu","year":"2025","unstructured":"Fu\u00a0Y, Zhou\u00a0J, Chen\u00a0X et\u00a0al (2025) Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction. Cell Commun Signal 23(1):480","journal-title":"Cell Commun Signal"},{"issue":"9","key":"2570_CR72","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/hed.27825","volume":"46","author":"JR Janopaul-Naylor","year":"2024","unstructured":"Janopaul-Naylor\u00a0JR, Sanda\u00a0MG, Zhong\u00a0J et\u00a0al (2024) Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial. Head Neck 46(9):2292\u20132300","journal-title":"Head Neck"},{"issue":"5","key":"2570_CR73","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee\u00a0JH, Long\u00a0GV, Boyd\u00a0S et\u00a0al (2017) Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28(5):1130\u20131136","journal-title":"Ann Oncol"},{"issue":"22","key":"2570_CR74","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-16-0613","volume":"22","author":"L Xi","year":"2016","unstructured":"Xi\u00a0L, Pham\u00a0TH, Payabyab\u00a0EC et\u00a0al (2016) Circulating Tumor DNA as an Early Indicator of Response to T\u2011cell Transfer Immunotherapy in Metastatic Melanoma. Clin Cancer Res 22(22):5480\u20135486","journal-title":"Clin Cancer Res"},{"key":"2570_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007369","volume":"11","author":"S Wu","year":"2023","unstructured":"Wu\u00a0S, Zhan\u00a0W, Liu\u00a0L et\u00a0al (2023) Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB\u2013IV NSCLC (LCDigital-IO Study): a multicenter retrospective study. J\u00a0Immunother Cancer 11:e007369","journal-title":"J Immunother Cancer"},{"key":"2570_CR76","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1754-9485.13426","volume":"66","author":"G Kothari","year":"2022","unstructured":"Kothari\u00a0G (2022) Role of radiomics in predicting immunotherapy response. J\u00a0Med Imaging Radiat Oncol 66:575\u2013591","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"2570_CR77","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2172926","volume":"19","author":"E Rossi","year":"2023","unstructured":"Rossi\u00a0E, Boldrini\u00a0L, Maratta\u00a0MG, Gatta\u00a0R, Votta\u00a0C, Tortora\u00a0G, Schinzari\u00a0G (2023) Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study. Hum Vaccin Immunother 19(1):2172926","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"2570_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03724-3","volume":"73","author":"W Cai","year":"2024","unstructured":"Cai\u00a0W, Wu\u00a0X, Guo\u00a0K et\u00a0al (2024) Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients. Cancer Immunol Immunother 73(8):153","journal-title":"Cancer Immunol Immunother"},{"key":"2570_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04004-x","volume":"21","author":"B Farina","year":"2023","unstructured":"Farina\u00a0B, Ramos Guerra\u00a0AD, Bermejo-Pel\u00e1ez\u00a0D et\u00a0al (2023) Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1\/PD-L1 immunotherapy in advanced NSCLC patients. J\u00a0Transl Med 21:article","journal-title":"J Transl Med"},{"key":"2570_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00454-z","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang\u00a0Y, Hu\u00a0H, Zhou\u00a0S et\u00a0al (2023) PET-based radiomics visualizes tumor-infiltrating CD8 T cell exhaustion to optimize radiotherapy\/immunotherapy combination in mouse models of lung cancer. Biomark Res 11:article","journal-title":"Biomark Res"},{"issue":"1","key":"2570_CR81","doi-asserted-by":"publisher","first-page":"392","DOI":"10.7150\/thno.87243","volume":"14","author":"H He","year":"2024","unstructured":"He\u00a0H, Qi\u00a0X, Fu\u00a0H et\u00a0al (2024) Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics 14(1):392\u2013405","journal-title":"Theranostics"},{"key":"2570_CR82","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s43018-022-00416-8","volume":"3","author":"R Vanguri","year":"2022","unstructured":"Vanguri\u00a0R, Luo\u00a0J, Aukerman\u00a0AT et\u00a0al (2022) Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer 3:1151\u20131164","journal-title":"Nat Cancer"},{"issue":"1","key":"2570_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31535-6","volume":"13","author":"J Kong","year":"2022","unstructured":"Kong\u00a0J, Ha\u00a0D, Lee\u00a0J et\u00a0al (2022) Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun 13(1):3703","journal-title":"Nat Commun"},{"key":"2570_CR84","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1002\/mp.15649","volume":"49","author":"F Romano","year":"2022","unstructured":"Romano\u00a0F, Bailat\u00a0C, Jorge\u00a0PG et\u00a0al (2022) Ultra-high dose rate dosimetry: Challenges and opportunities for FLASH radiation therapy. Med Phys 49:4912\u20134932","journal-title":"Med Phys"},{"issue":"20","key":"2570_CR85","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia\u00a0SJ, Villegas\u00a0A, Daniel\u00a0D, Vicente\u00a0D, Murakami\u00a0S, Hui\u00a0R, Yokoi\u00a0T, Chiappori\u00a0A, Lee\u00a0KH, de Wit\u00a0M, Cho\u00a0BC, Bourhaba\u00a0M, Quantin\u00a0X, Tokito\u00a0T, Mekhail\u00a0T, Planchard\u00a0D, Kim\u00a0YC, Karapetis\u00a0CS, Hiret\u00a0S, Ostoros\u00a0G, Kubota\u00a0K, Gray\u00a0JE, Paz-Ares\u00a0L, de Castro Carpe\u00f1o\u00a0J, Wadsworth\u00a0C, Melillo\u00a0G, Jiang\u00a0H, Huang\u00a0Y, Dennis\u00a0PA, \u00d6zg\u00fcro\u011flu\u00a0M, PACIFIC Investigators (2017) Durvalumab after Chemoradiotherapy in Stage\u00a0III Non-Small-Cell Lung Cancer. N Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"21","key":"2570_CR86","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.18632\/oncotarget.27987","volume":"12","author":"Y Yu","year":"2021","unstructured":"Yu\u00a0Y, Zakeri\u00a0K, Lee\u00a0N (2021) Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy? Oncotarget 12(21):2223\u20132226","journal-title":"Oncotarget"},{"key":"2570_CR87","unstructured":"Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetna\u0142 M, Delord JP, Mes\u00eda R, Taberna M, Waldron JN, Simon C, Gr\u00e9goire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a\u00a0randomised, double-blind, phase\u00a03\u00a0trial. Lancet Oncol. 2024 May;25(5):572\u2013587."}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02570-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02570-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02570-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:01:38Z","timestamp":1783670498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02570-9"}},"subtitle":["A\u00a0systematic review"],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":87,"alternative-id":["2570"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02570-9","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.G.\u00a0Cattaneo, E.\u00a0Pozzo, G.\u00a0Panza, G.\u00a0Chiloiro, A.\u00a0Romano, M.\u00a0Galetto, M.\u00a0Nardini, L.\u00a0Placidi, M.A.\u00a0Gambacorta and L.\u00a0Boldrini declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}